ReviewInternational journal of molecular sciences2013
The potential role of lycopene for the prevention and therapy of prostate cancer: from molecular mechanisms to clinical evidence.
Review in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 6 citations in OpenAlex.
- Investigating the effects of lycopene and green tea on the metabolome of men at risk of prostate cancer: The ProDiet randomised controlled trial.International journal of cancer · 2019Trial
- Nutraceuticals in Uro-Oncology: A Structured Expert Review and Precision-Oriented Framework.Nutrients · 2026Review
- Natural Products in Prostate Cancer: Crosstalk Among the Gut Microbiome, Androgen Receptor Signaling, and Epigenetic Regulation.International journal of molecular sciences · 2026Review
- Mitochondrial-targeted actions of lycopene: evidence, mechanisms and future directions.Frontiers in pharmacology · 2026Review
- Exploring the Optical Properties of Carotenoid-Based Nanoparticles: The Role of Terminal Groups.Molecules (Basel, Switzerland) · 2024Article
- Agri-Food Waste Recycling for Healthy Remedies: Biomedical Potential of Nutraceuticals from Unripe Tomatoes (Foods (Basel, Switzerland) · 2024Review
- Network Proteins of Human Sortilin1, Its Expression and Targetability Using Lycopene.Life (Basel, Switzerland) · 2024Article
- Lycopene: A Potent Antioxidant with Multiple Health Benefits.Journal of nutrition and metabolism · 2024Review
- Oranges, potatoes and phytonutrients; why are they good for human health.PHYTOnutrients (Karachi, Pakistan) · 2024Article
- Therapeutic Approaches to Increase the Survival Rate of Cancer Patients in the Younger and Older Population.Current aging science · 2024Review
- Biological activities of extracts and compounds from Thai Kae-Lae (Maclura cochinchinensis (Lour.) Corner).BMC complementary medicine and therapies · 2023Article
- Biochemical Evaluation of Some Fruit Characteristics of Blueberry Progenies Obtained from 'Simultan × Duke'.ACS omega · 2023Article
- Sustainable Valorization of Tomato Pomace (Animals : an open access journal from MDPI · 2022Review
- Lycopene Improves Metabolic Disorders and Liver Injury Induced by a Hight-Fat Diet in Obese Rats.Molecules (Basel, Switzerland) · 2022Article
- Chemopreventive Potential of Dietary Nanonutraceuticals for Prostate Cancer: An Extensive Review.Frontiers in oncology · 2022Review
- An integrated genomic and biochemical approach to investigate the potentiality of heirloom tomatoes: Breeding resources for food quality and sustainable agriculture.Frontiers in plant science · 2022Article
- Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer.Molecules (Basel, Switzerland) · 2021Review
- Valorization of Tomato Waste as a Source of Carotenoids.Molecules (Basel, Switzerland) · 2021Review
- Article
- Carotenoids and Some Other Pigments from Fungi and Yeasts.Metabolites · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lycopene is a phytochemical that belongs to a group of pigments known as carotenoids. It is red, lipophilic and naturally occurring in many fruits and vegetables, with tomatoes and tomato-based products containing the highest concentrations of bioavailable lycopene. Several epidemiological studies have linked increased lycopene consumption with decreased prostate cancer risk. These findings are supported by in vitro and in vivo experiments showing that lycopene not only enhances the antioxidant response of prostate cells, but that it is even able to inhibit proliferation, induce apoptosis and decrease the metastatic capacity of prostate cancer cells. However, there is still no clearly proven clinical evidence supporting the use of lycopene in the prevention or treatment of prostate cancer, due to the only limited number of published randomized clinical trials and the varying quality of existing studies. The scope of this article is to discuss the potential impact of lycopene on prostate cancer by giving an overview about its molecular mechanisms and clinical effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.